|

Pegylated liposomal doxorubicin Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: Caelyx, Doxil, Lipodox, PLD

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Yonsei University1
  • Verastem, Inc.1
  • TILT Biotherapeutics Ltd.1
  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1
  • InxMed (Shanghai) Co., Ltd.1

Indications

  • Cancer5
  • Low-Grade Serous Ovarian Cancer1
  • Clear Cell Carcinoma1
  • Vagina Neoplasm1
  • Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin1

Other2 trials

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Phase 2

Phoenix, Arizona1 trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3

Aurora, Colorado1 trial

A Study of ZN-c3 in Patients With Ovarian Cancer

Site 0264

Phase 1

Rochester, Minnesota1 trial

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Mayo Clinic

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.